心臓マーカー検査市場：製品、バイオマーカー、検査タイプ、疾患別-2025-2030年の世界予測

心臓マーカー検査市場は、2023年に51億米ドルと評価され、2024年には55億米ドルに達すると予測され、CAGR 7.90％で成長し、2030年には86億9,000万米ドルに達すると予測されています。

心臓マーカー検査は、血液中の特定の生体分子を検出することで、主に心臓発作や急性冠症候群などの心血管疾患を診断・管理する重要なプロセスです。心臓マーカー検査の必要性は、効果的な患者管理と治療に必要な迅速で正確な診断を提供する役割に由来します。この検査は、特に胸痛などの症状を示す患者や心筋梗塞の可能性がある患者など、緊急の場面で極めて重要です。心臓マーカー検査のアプリケーションは、病院、クリニック、診断研究所に及び、治療の意思決定にタイムリーで信頼性の高いデータを必要とするヘルスケア専門家が主要なエンドユーザーとなります。

心臓マーカー検査の市場成長は、心血管疾患の有病率の上昇、人口の高齢化、診断技術の進歩に大きく影響されます。この分野で注目すべきビジネスチャンスには、迅速な結果を提供し、その利便性と効率性から需要が高まっているポイントオブケア検査機器の開発と統合が含まれます。高感度アッセイシステムの出現は、技術革新と市場浸透向上の機会をさらにもたらします。こうした機会にもかかわらず、高度な検査技術の高コスト、規制の複雑さ、償還の問題といった課題が、市場の成長に制約をもたらしています。さらに、市場は代替診断法との競合に直面しており、これが市場拡大の妨げになる可能性もあります。

イノベーションと研究開発の機会は、包括的な心臓プロファイルを提供するマルチマーカー検査パネルの開発と、心臓イベントの診断におけるより優れた予測分析のための人工知能の組み込みにあります。最先端の研究は、診断精度と予後予測価値を高める新規心臓バイオマーカーの同定にも焦点を当てることができます。市場の特性として、急速な技術進歩と競合情勢があり、継続的な技術革新と戦略的提携が必要です。企業は、研究開発への投資、製品ポートフォリオの拡大、医療提供者の進化するニーズに対応するための技術的進歩の採用によって成長を実現し、市場の妥当性と競争力を確保することができます。

市場力学：急速に進化する心臓マーカー検査市場の主要市場インサイトを公開

心臓マーカー検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心血管疾患の流行と効果的な診断の必要性
  • 世界の心臓マーカーのポイントオブケア検査の台頭
  • 心血管疾患の早期発見とスクリーニングを奨励する取り組み
• 市場抑制要因
  • 心臓マーカー検査製品の不都合なリコール
• 市場機会
  • 検査技術の進歩と新しいバイオマーカーの統合
  • 個別化医療へのシフトとテーラーメイド心臓マーカー検査のイントロダクション
• 市場の課題
  • 心臓マーカー検査の不正確さと限定された特異性に関する懸念

ポーターのファイブフォース：心臓マーカー検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、心臓マーカー検査市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：心臓マーカー検査市場における外部からの影響の把握

外部マクロ環境要因は、心臓マーカー検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析心臓マーカー検査市場における競合情勢の把握

心臓マーカー検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス心臓マーカー検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、心臓マーカー検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨心臓マーカー検査市場における成功への道筋を描く

心臓マーカー検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の有病率と効果的な診断の必要性
    • 世界中で心臓マーカーのポイントオブケア検査が増加
    • 心血管疾患の早期発見とスクリーニングを促進する取り組み
  • 抑制要因
    • 心臓マーカー検査製品の有害リコール
  • 機会
    • 検査技術の進歩と新しいバイオマーカーの統合
    • 個別化医療への移行とテーラーメイド医療のイントロダクション
  • 課題
    • 心臓マーカー検査の不正確さと限定的な特定性に関連する懸念
• 市場セグメンテーション分析
  • 製品：心臓マーカー検査における診断機器の重要性
  • バイオマーカー：心臓評価におけるトロポニンバイオマーカーの利用増加
  • 検査の種類：ポイントオブケア検査の採用の増加
  • 疾患：心筋梗塞における心臓マーカー検査の広範な応用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 心臓マーカー検査市場：製品別

• 機器
  • 化学発光
  • エリサ
  • 免疫クロマトグラフィー
  • 免疫蛍光法
• 試薬とキット

第7章 心臓マーカー検査市場バイオマーカー

• BNPまたはNT-ProBNP
• セラチンキナーゼ-MB
• hs-CRP
• ミオグロビン
• トロポニン

第8章 心臓マーカー検査市場テストの種類別

• 臨床検査
• ポイントオブケア検査

第9章 心臓マーカー検査市場：疾患別

• うっ血性心不全
• 心筋梗塞

第10章 南北アメリカの心臓マーカー検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の心臓マーカー検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの心臓マーカー検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • マインドレイ、新たなアッセイの発売により心臓バイオマーカーポートフォリオを拡大
  • NOWDxとAeenaDxが合併を発表
  • パスカインド・ラボとロシュ・ダイアグノスティクスが心臓バイオマーカーのリリースで提携
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Assure Tech（Hangzhou）Co., Ltd.
• Atlas Medical GmbH
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Biomerieux SA
• Boditech Med Inc.
• Charles River Laboratories International, Inc.
• Cleerly, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• HyTest Ltd.
• Laboratory Corporation of America Holdings
• LightDeck Diagnostics
• Merck KGaA
• Natera, Inc.
• PerkinElmer Inc.
• Qiagen N.V.
• Quest Diagnostics
• QuidelOrtho Corporation
• Randox Laboratories Ltd.
• Sekbio
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Tosoh Corporation

LIST OF FIGURES

• FIGURE 1. CARDIAC MARKER TESTING MARKET RESEARCH PROCESS
• FIGURE 2. CARDIAC MARKER TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CARDIAC MARKER TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CARDIAC MARKER TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CARDIAC MARKER TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY BNP OR NT-PROBNP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY CERATINE KINASE-MB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY HS-CRP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CARDIAC MARKER TESTING MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. CANADA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CARDIAC MARKER TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 73. CHINA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 74. CHINA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. INDIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 78. INDIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 79. INDIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. ITALY CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 164. ITALY CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 165. ITALY CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. POLAND CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 184. POLAND CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 185. POLAND CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. QATAR CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 189. QATAR CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 190. QATAR CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM CARDIAC MARKER TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM CARDIAC MARKER TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM CARDIAC MARKER TESTING MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM CARDIAC MARKER TESTING MARKET SIZE, BY TYPE OF TESTING, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM CARDIAC MARKER TESTING MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 236. CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. CARDIAC MARKER TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Cardiac Marker Testing Market was valued at USD 5.10 billion in 2023, expected to reach USD 5.50 billion in 2024, and is projected to grow at a CAGR of 7.90%, to USD 8.69 billion by 2030.

Cardiac marker testing is a critical process in diagnosing and managing cardiovascular diseases, primarily heart attacks and acute coronary syndromes, through the detection of specific biomolecules in the blood. The necessity of cardiac marker testing stems from its role in providing rapid, accurate diagnosis necessary for effective patient management and treatment. This testing is crucial in emergency settings, particularly for patients exhibiting symptoms such as chest pain or other potential indications of myocardial infarction. The applications of cardiac marker testing extend to hospitals, clinics, and diagnostic laboratories, with key end-users being healthcare professionals who require timely and reliable data to inform treatment decisions.

Market growth for cardiac marker testing is significantly influenced by the rising prevalence of cardiovascular diseases, an aging population, and advancements in diagnostic technologies. Notable opportunities in this field include the development and integration of point-of-care testing devices, which offer quick results and are increasingly in demand due to their convenience and efficiency. The advent of high-sensitivity assay systems further presents opportunities for innovation and improved market penetration. Despite these opportunities, challenges such as high cost of advanced testing technologies, regulatory complexities, and reimbursement issues pose limitations to market growth. Additionally, the market faces competition from alternative diagnostic modalities, which might hinder its expansion.

Innovation and research opportunities lie in the development of multi-marker testing panels that provide comprehensive cardiac profiles and the incorporation of artificial intelligence for better predictive analytics in diagnosing cardiac events. Cutting-edge research could also focus on identifying novel cardiac biomarkers that enhance diagnostic accuracy and prognostic value. The nature of the market is characterized by rapid technological advancements and a competitive landscape, necessitating continuous innovation and strategic partnerships. Businesses can achieve growth by investing in R&D, expanding their product portfolios, and adopting technological advancements to meet the evolving needs of healthcare providers, ensuring market relevance and competitiveness.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Marker Testing Market

The Cardiac Marker Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cardiovascular diseases and need for effective diagnostics
  • Rise of point-of-care testing for cardiac markers worldwide
  • Initiatives encouraging early detection and screening of cardiovascular diseases
• Market Restraints
  • Adverse recalls of cardiac marker testing products
• Market Opportunities
  • Advancements in testing technologies and integration of new biomarkers
  • Shift toward personalized medicine and introduction of tailored cardiac marker testing
• Market Challenges
  • Concerns associated with inaccuracy and limited specificity of cardiac marker testing

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Marker Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Marker Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Marker Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Marker Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Marker Testing Market

A detailed market share analysis in the Cardiac Marker Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Marker Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Marker Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Marker Testing Market

A strategic analysis of the Cardiac Marker Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Assure Tech (Hangzhou) Co., Ltd., Atlas Medical GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biomerieux SA, Boditech Med Inc., Charles River Laboratories International, Inc., Cleerly, Inc., Danaher Corporation, DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffmann-La Roche AG, HyTest Ltd., Laboratory Corporation of America Holdings, LightDeck Diagnostics, Merck KGaA, Natera, Inc., PerkinElmer Inc., Qiagen N.V., Quest Diagnostics, QuidelOrtho Corporation, Randox Laboratories Ltd., Sekbio, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.

Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments and Reagents & Kits. The Instruments is further studied across Chemiluminescence, ELISA, Immunochromatography, and Immunofluorescence.
• Based on Biomarker, market is studied across BNP Or NT-ProBNP, Ceratine Kinase-MB, hs-CRP, Myoglobin, and Troponin.
• Based on Type of Testing, market is studied across Laboratory Testing and Point-Of-Care Testing.
• Based on Disease, market is studied across Congestive Heart Failure and Myocardial Infarction.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cardiovascular diseases and need for effective diagnostics
    • 5.1.1.2. Rise of point-of-care testing for cardiac markers worldwide
    • 5.1.1.3. Initiatives encouraging early detection and screening of cardiovascular diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Adverse recalls of cardiac marker testing products
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in testing technologies and integration of new biomarkers
    • 5.1.3.2. Shift toward personalized medicine and introduction of tailored cardiac marker testing
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with inaccuracy and limited specificity of cardiac marker testing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significance of diagnostic instruments in cardiac marker testing
  • 5.2.2. Biomarker: Rising utilization of Troponin biomarker for cardiac assessment
  • 5.2.3. Type of Testing: Increasing adoption of Point-of-Care testing
  • 5.2.4. Disease: Extensive applications of cardiac marker testing in myocardial infarction
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cardiac Marker Testing Market, by Product

• 6.1. Introduction
• 6.2. Instruments
  • 6.2.1. Chemiluminescence
  • 6.2.2. ELISA
  • 6.2.3. Immunochromatography
  • 6.2.4. Immunofluorescence
• 6.3. Reagents & Kits

7. Cardiac Marker Testing Market, by Biomarker

• 7.1. Introduction
• 7.2. BNP Or NT-ProBNP
• 7.3. Ceratine Kinase-MB
• 7.4. hs-CRP
• 7.5. Myoglobin
• 7.6. Troponin

8. Cardiac Marker Testing Market, by Type of Testing

• 8.1. Introduction
• 8.2. Laboratory Testing
• 8.3. Point-Of-Care Testing

9. Cardiac Marker Testing Market, by Disease

• 9.1. Introduction
• 9.2. Congestive Heart Failure
• 9.3. Myocardial Infarction

10. Americas Cardiac Marker Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Cardiac Marker Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Cardiac Marker Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays
  • 13.3.2. NOWDx and AeenaDx Announce Merger
  • 13.3.3. Pathkind Labs, Roche Diagnostics Partner to Release Cardiac Biomarker
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Assure Tech (Hangzhou) Co., Ltd.
• 4. Atlas Medical GmbH
• 5. Becton, Dickinson and Company
• 6. Bio-Rad Laboratories, Inc.
• 7. Bio-Techne Corporation
• 8. Biomerieux SA
• 9. Boditech Med Inc.
• 10. Charles River Laboratories International, Inc.
• 11. Cleerly, Inc.
• 12. Danaher Corporation
• 13. DiaSorin S.p.A.
• 14. Eurofins Scientific SE
• 15. F. Hoffmann-La Roche AG
• 16. HyTest Ltd.
• 17. Laboratory Corporation of America Holdings
• 18. LightDeck Diagnostics
• 19. Merck KGaA
• 20. Natera, Inc.
• 21. PerkinElmer Inc.
• 22. Qiagen N.V.
• 23. Quest Diagnostics
• 24. QuidelOrtho Corporation
• 25. Randox Laboratories Ltd.
• 26. Sekbio
• 27. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 28. Siemens Healthineers AG
• 29. Thermo Fisher Scientific Inc.
• 30. Tosoh Corporation